Jiangsu Lianhuan Pharmaceutical Co., Ltd.

Jiangsu Lianhuan Pharmaceutical Co., Ltd. was established in December 1999, initiated by Yangzhou Pharmaceutical Factory, which was founded in 1958. In March 2003, the company went public on the A-share market. After years of reform, innovation, and development, Jiangsu Lianhuan Pharmaceutical Co., Ltd. has grown into a national high-tech enterprise integrating R&D, production, and sales. It is ranked among the top 100 pharmaceutical enterprises in China and has achieved a series of developmental accomplishments. The company owns several subsidiaries, including Yangzhou Lianhuan Pharmaceutical Marketing, Lianhuan (Nanjing) Medical Technology, Nanjing Lianzhi Pharmaceutical Technology, and Chengdu Yazhong Biopharmaceuticals.The company has now formed two R&D platforms in Nanjing and Yangzhou, relying on an academician workstation and a doctoral workstation. It has established strong technical cooperation relationships with major institutions such as the Shanghai Institute of Pharmaceutical Research of the Chinese Academy of Sciences and China Pharmaceutical University. To date, the company has developed more than 10 national new drugs, including a Class I national new drug, as well as several generic drugs, and has obtained multiple invention patents. Its product portfolio covers five major series: urology (mainly including Alprostadil, Terazosin, etc.), antihistamines (mainly including Ebastine Tablets, Terfenadine Tablets, etc.), cardiovascular (mainly including Felodipine Tablets, Simvastatin Tablets, etc.), steroid hormones (mainly including Levonorgestrel, Danazol Capsules, etc.), and antibiotics (mainly including Azithromycin Tablets, Doxycycline Hyclate Tablets, etc.).In recent years, Lianhuan Pharmaceutical has adhered to technological innovation and pursued green development, striving to build a modern pharmaceutical enterprise. The company is forging ahead with full steam and accelerating progress on its "second entrepreneurial" journey.